Form 4: Ampersand Converts Preferred Stock to Common in IDXG

Ampersand 2018 Limited Partnership converted 28,000 shares of Series C Convertible Preferred Stock into 13,861,386 shares of Interpace Biosciences common stock.

Summary

• Ampersand 2018 Limited Partnership, a 10% owner of Interpace Biosciences, Inc. (IDXG), converted 28,000 shares of Series C Convertible Preferred Stock into 13,861,386 shares of common stock.
• The conversion occurred on January 20, 2026, at a conversion price of $2.02 per common share.
• Following the transaction, Ampersand 2018 Limited Partnership directly holds 13,861,386 shares of Interpace Biosciences common stock and 0 shares of Series C Convertible Preferred Stock.
• The Series C Preferred Shares had an initial stated value of $1,000 per share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral event, as it represents the execution of a pre-existing convertible security. The conversion by a significant owner could be seen as a positive sign of commitment, but it also introduces dilution.

Positives

• Conversion of preferred stock into common stock can simplify the capital structure.
• Increased common stock ownership by a significant investor (10% owner) could signal long-term confidence.

Negatives

• The conversion increases the number of outstanding common shares, potentially diluting existing common shareholders.

Risks

• Potential dilution for existing common shareholders due to the issuance of 13,861,386 new common shares upon conversion.
• The reporting persons (Ampersand 2018 Limited Partnership, AMCLP, and AMCLLC) disclaim beneficial ownership except to the extent of their pecuniary interest, which could imply a nuanced view on their long-term commitment or control.

Future Outlook

This filing is a historical transaction report and does not contain forward-looking statements or guidance regarding Interpace Biosciences' future performance or strategic direction.

Management Comments

• Each of the Investor, AMCLP and AMCLLC disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any.

Industry Context

StockSavvy.ai notes that conversions of preferred stock to common stock are a standard mechanism for investors to realize their equity stake, often occurring as a company matures or as part of a pre-defined investment agreement. This specific conversion by a 10% owner indicates a significant shift in their holding structure within Interpace Biosciences.

Comparison to Industry Standards

• Conversions of preferred stock are common in the biotechnology and diagnostics industry, where companies often raise capital through convertible securities to fund research and development or expansion.
• The conversion price of $2.02 per share for Interpace Biosciences common stock should be evaluated against the company's current market price and historical trading range to assess the implied valuation at the time of conversion relative to peers like Exact Sciences (EXAS) or Guardant Health (GH) which also operate in diagnostics.
• The substantial number of common shares issued (13.86 million) represents a significant portion of the company's potential outstanding shares, warranting comparison to similar capital structure changes in companies of comparable market capitalization.

Stakeholder Impact

• Shareholders: Existing common shareholders will experience dilution due to the issuance of 13,861,386 new common shares.
• Ampersand 2018 Limited Partnership: Their investment structure shifts from preferred stock to common stock, aligning their interests more directly with common shareholders.

Key Dates

Recommendation

This Form 4 reports a conversion of preferred stock to common stock by a significant investor. While it indicates the execution of a prior investment agreement and a shift in the investor's equity structure, it doesn't provide new fundamental information about the company's operational performance or strategic direction that would warrant a strong buy or sell recommendation. The dilution from the conversion is a factor, but the overall impact on the stock's value depends on the company's underlying business performance and future prospects, which are not detailed in this filing. Therefore, a "hold" recommendation is appropriate, pending further operational updates.

Keywords

Interpace Biosciences, IDXG, Ampersand 2018 Limited Partnership, Series C Preferred Stock, Common Stock, Convertible Securities, Beneficial Ownership, SEC Form 4, Capital Structure, Dilution